ArticleObesity surgery2025
Tailored Biliopancreatic Limb Length to 40% of Total Small Bowel Length in One Anastomosis Gastric Bypass (TABLE-40): Protocol of a Prospective Randomized Controlled Trial.
Article in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06829381 (Tailoring One-Anastomosis Gastric Bypass Based on Total Small Bowel Length - A Randomized Controlled Trial), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tailoring One-Anastomosis Gastric Bypass Based on Total Small Bowel Length - A Randomized Controlled Trial
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Long-Term Outcomes of One-Anastomosis Gastric Bypass: A Systematic Review of Studies with at Least 10 Years of Follow-Up.Obesity surgery · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne anastomosis gastric bypass (OAGB) is the most common metabolic and bariatric surgery (MBS) in Israel, recognized for its effectiveness in achieving sustainable weight loss and mitigating obesity-related diseases. The metabolic outcomes of OAGB are significantly influenced by the length of the biliopancreatic limb (BPL). The objective of this study is to determine whether tailoring the BPL length to the total small bowel length (TSBL) results in more effective weight loss compared to patients undergoing OAGB with a fixed BPL of 180 cm. Efficacy and safety of this approach will also be evaluated, ensuring it does not lead to long-term morbidity or negatively impact patients' quality of life.
methodsThis multicenter, prospective, randomized trial will enroll at least 200 participants undergoing OAGB across three centers. Participants, aged 18 and older, will be randomized into two groups: one group will undergo a tailored BPL length based on TSBL (40%), while the control group will receive a standard BPL length of 180 cm. The primary endpoint is comparison of total weight loss after 1 and 3 years. Secondary endpoints include postoperative complications, quality of life, and improvements in obesity-related diseases.
resultsThe study will collect and analyze data as outlined in the protocol. The results will be reported upon completion of data collection and analysis.
conclusionsThe TABLE-40 study will provide robust evidence on whether tailoring the BPL to 40% of TSBL offers higher weight loss outcomes compared to a fixed-length approach in OAGB. By assessing both efficacy and safety across multiple centers, the trial aims to inform best practices in limb length selection and optimize long-term outcomes for patients undergoing OAGB.
trial registrationThis study was registered at Clinicaltrials.gov (NCT06829381) on 29/1/2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.